Prostatilen

Prostatilen is a registered pharmaceutical preparation derived from the prostate glands of mature cattle. Its active substance is a complex of low-molecular-weight regulatory peptides isolated by ultrafiltration of bovine prostatic tissue. These oligopeptides are hypothesized to enter the cell nucleus and interact with gene promoter regions, stimulating transcription and protein synthesis in a tissue-selective manner that preferentially acts on prostate cells—a mechanism described by its developers as organotropic bioregulation.

Several pharmacological pathways have been characterized in Russian clinical and experimental research.

• Antiplatelet and hemostatic activity: the extract reduces platelet aggregation, interferes with platelet adhesion at sites of endothelial injury, and prolongs coagulation time, thereby improving microcirculation within prostatic tissue. A 2024 Pharmaceutical Chemistry Journal analysis identified a peptide fragment within bovine prostate extract homologous to the chemokine MCP-1 that suppressed monocytic cell migration and platelet aggregation in vitro.

• Anti-inflammatory activity: the extract enhances synthesis of antihistamine and antiserotonin antibodies, reducing local inflammatory mediators in prostatic tissue.

• Immunotropic activity: increases functional activity of T-lymphocytes, natural killer cells, and phagocytes; in one series the CD4+/CD8+ ratio increased from 1.02 to 1.52 (p<0.05).

• Myotropic effect on smooth muscle: reported to increase detrusor basal tone while reducing pathological spontaneous contractility, supporting improved urinary flow.

The complete receptor target profile and full peptide sequence repertoire remain incompletely characterized in accessible English-language literature.

Clinical evidence for Prostatilen derives almost entirely from Russian and Ukrainian clinical literature, predominantly published in Russian-language journals. Large-scale double-blinded placebo-controlled trials have not been conducted, and independent replication in Western peer-reviewed literature is absent. The evidence should be interpreted accordingly.

In the earliest substantial human trial (Tkachuk et al, 1991, n=307 men with chronic prostatitis, ages 18-70), intramuscular Prostatilen 5-10 mg for 10 days produced clinical improvement in nearly all participants; sustained effects at 6 months were documented in 55.4% of cases. Among 230 patients with concurrent sexual dysfunction, 102 recovered completely and 96 showed partial improvement (PMID 1823683 describes a concurrent series of 37 chronic prostatitis and 15 BPH patients with improvements in pain, dysuria, uroflowmetry, and reduced residual urine).

A series studying benign prostatic hyperplasia (n=56) at Saint Petersburg's First Pavlov State Medical University used 30 mg rectal suppositories nightly for 15 days, repeated quarterly over one year. Voiding frequency fell from 9.4±1.4 to 5.3±1.1 times daily (p<0.05) and maximum urinary flow rate rose from 7.9±2.5 to 17.8±1.7 mL/s (p<0.001) with no adverse events during follow-up.

A 2022 randomized comparative study (PMID 36318852, n=98 men, ages 25-45) assigned patients with chronic abacterial prostatitis and impaired spermatogenesis to Prostatilen AC (with added L-arginine and zinc, n=49) or standard Prostatilen (n=49) for 10 days. Total motile sperm fraction improved 14.3% in the AC group versus 4.1% in controls; abnormal morphology decreased 12.4% versus 6.5%; differences were statistically significant.

An animal study (PMID 23116023, 40 Sprague-Dawley rats with experimentally induced prostatitis) showed Prostatilen AC suppositories reduced prostate weight, lowered C-reactive protein and ceruloplasmin, elevated serum testosterone, and normalized urine output. A large observational series of 1,115 patients (PMID 14708243, Urologiia 2003) associated Prostatilen with correction of hemocoagulation abnormalities, improved immune markers, and suppression of prostatic and renal inflammation.

Typical dosage: 10 mg (daily for cycles).

The following dosage information reflects protocols described in Russian clinical literature and available product labeling. This is educational information, not medical advice.

Intramuscular injection: 5 to 10 mg administered once daily for 5 to 15 days. The Tkachuk 1991 prostatitis series used 5-10 mg IM for 10 days. A pyelonephritis study protocol used 5 mg IM daily for 5 days.

Rectal suppository (standard Prostatilen): one suppository (30 to 50 mg) inserted rectally once daily after a bowel movement, with the patient lying prone for approximately 30 to 40 minutes following insertion to optimize mucosal absorption. For chronic prostatitis, a minimum course of 10 consecutive days is reported; for benign prostatic hyperplasia, a minimum of 15 days. The commercially marketed formulation is 50 mg per suppository.

Prostatilen AC (enhanced formulation containing 100 mg L-arginine and 23 mg zinc per suppository): one suppository rectally once daily for 10 days, as used in the 2022 spermatogenesis study (PMID 36318852).

Retreat courses: clinical series employed retreatment at 3-to-6-month intervals. The BPH suppository study used quarterly retreatment over 12 months. The combination Prostatilen-plus-Thymogen trial used a single 5-day course alongside antibiotics.

Prostatilen is registered as a pharmaceutical drug in Russia and several post-Soviet countries. These regimens have not been validated in FDA or EMA submissions. Individuals should consult a licensed healthcare provider before initiating treatment.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Published Russian urology literature describes two well-characterized pharmaceutical combination approaches.

Prostatilen plus Thymogen (immunomodulator): A 63-patient trial at Saint Petersburg State Medical University assigned patients with chronic bacterial prostatitis to Thymogen alone (100 mcg/day), Prostatilen suppositories alone (30 mg/day), or both together for 5 days alongside antibiotic therapy. The combination group maintained clinical remission beyond 5 months in 84% of patients, versus 75% beyond 4 months for Prostatilen monotherapy. The rationale is complementary immunomodulation: Prostatilen provides organotropic prostatic support while Thymogen, a synthetic thymopoietin-analogue dipeptide, activates systemic T-lymphocyte function.

Prostatilen AC (zinc and L-arginine formulation): This registered pharmaceutical combination adds zinc, concentrated in prostatic tissue and required for spermatogenesis and testosterone metabolism, and L-arginine, a nitric oxide precursor supporting vascular tone. The 2022 randomized study (PMID 36318852, n=98) confirmed statistically superior sperm motility and morphology outcomes versus standard Prostatilen alone.

Combination with alpha-blockers: Studies of the closely related prostatic bioregulatory suppository Uroprost-D alongside tamsulosin 0.4 mg for chronic abacterial prostatitis/CPPS showed sustained NIH-CPSI score improvement (mean 9.2 at day 60) versus indomethacin plus tamsulosin (mean 19.3). Direct comparative data pairing Prostatilen specifically with alpha-blockers are limited; this finding involves a related but distinct formulation.

Prostatilen is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Well-tolerated

Prostatilen has a generally favorable reported safety profile in available clinical studies, though the evidence base is limited by the absence of large placebo-controlled trials and independent Western replication. Across multiple series totaling several hundred patients, no serious adverse events were reported. Authors of the 30-year pharmacological review stated that peptide preparations of this type do not produce side effects on organ structure and function and show no mutagenic activity. No adverse events were recorded in the 1-year BPH suppository series or in the 98-patient 2022 spermatogenesis trial.

Rectal suppository administration: mild transient itching or burning in the perianal or rectal area has been reported in some patients; these effects are described as minor and self-limiting. Rare hypersensitivity reactions including skin rash are possible and represent grounds for discontinuation.

Contraindications in product labeling: known hypersensitivity to bovine-derived materials or suppository excipients; not approved for use in patients under 18 years of age.

Potential drug interactions: because Prostatilen reduces platelet aggregation and prolongs coagulation time, caution is warranted in patients receiving anticoagulants (warfarin, heparins) or antiplatelet agents. Formal pharmacokinetic interaction studies have not been published in accessible English-language literature.

Prostatilen is a registered pharmaceutical drug in Russia, not a compounding or grey-market research peptide, which gives it somewhat more regulatory oversight than many peptide bioregulators sold in Western markets. Nevertheless, it has not undergone FDA or EMA review, and long-term safety data beyond one year are not available in retrievable published studies.